Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma
|2||Not yet recruiting||
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
† Study has passed its completion date and status has not been verified in more than two years.